Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last €22.79 EUR
Change Today +0.291 / 1.29%
Volume 295.1K
QIA On Other Exchanges
Symbol
Exchange
Xetra
NASDAQ GS
As of 3:06 PM 05/22/15 All times are local (Market data is delayed by at least 15 minutes).

qiagen n.v. (QIA) Snapshot

Open
€22.46
Previous Close
€22.50
Day High
€22.79
Day Low
€22.40
52 Week High
04/10/15 - €24.15
52 Week Low
10/16/14 - €16.10
Market Cap
5.3B
Average Volume 10 Days
363.7K
EPS TTM
€0.66
Shares Outstanding
232.0M
EX-Date
--
P/E TM
37.8x
Dividend
--
Dividend Yield
--
Current Stock Chart for QIAGEN N.V. (QIA)

qiagen n.v. (QIA) Related Businessweek News

No Related Businessweek News Found

qiagen n.v. (QIA) Details

QIAGEN N.V. provides sample to insight solutions that transform biological samples into valuable molecular insights worldwide. It offers sample technologies to isolate, purify, and stabilize nucleic acids and proteins in plasmid deoxyribonucleic acid (DNA) purification, ribonucleic acid purification and stabilization, genomic and viral nucleic acid purification, DNA cleanup after polymerase chain reaction (PCR) and sequencing, and library preparation for sequencing applications; and assay technologies to detect molecular targets. The company also offers ingenuity variant analysis, a cloud-based platform to evaluate data generated by NGS technologies; CLC cancer research workbench, a cancer-focused informatics solution; and GeneGlobe, a Web-based portal that enables researchers to search and select from pre-designed and custom PCR assay kits and NGS assay panels. In addition, it provides co-development, technology licenses and patent sales, and custom services, such as whole genome amplification services, DNA sequencing, and non-cGMP DNA production. Further, the company offers instrumentation systems for laboratories to perform nucleic acid sample preparation, assay setup, target detection, and interpretation of genomic information. Its automation platforms include QIAsymphony, a modular system; EZ1 Advanced XL for automated nucleic acid purification; QIAcube, a sample processing instrument; QIAcube HT for automated nucleic acid purification; Rotor-Gene Q, a rotary real-time PCR cycler system; PyroMark, a high-resolution detection platform; QIAgility, a compact benchtop instrument; QIAxcel for nucleic acid separation; and ESEQuant Tube Scanners. The company serves molecular diagnostics, applied testing, pharma, and academia customers. It has collaboration agreement with Astellas Pharma Inc., AstraZeneca PLC, Eli Lilly and Company, Exosome Diagnostics Inc., and Novartis AG. QIAGEN N.V. was founded in 1986 and is headquartered in Venlo, the Netherlands.

4,300 Employees
Last Reported Date: 05/7/15
Founded in 1986

qiagen n.v. (QIA) Top Compensated Officers

Chief Executive Officer and Managing Director
Total Annual Compensation: $1.9M
Chief Financial Officer and Managing Director
Total Annual Compensation: $811.0K
Compensation as of Fiscal Year 2014.

qiagen n.v. (QIA) Key Developments

QIAGEN Opens New Office in Kuala Lumpur as Business Expands in Malaysia

Qiagen NV announced the opening of its new principal office in Malaysia to serve its growing base of customers for Sample to Insight solutions, enabling them to help fight diseases using molecular diagnostics, break new ground in research for the life sciences and pharmaceutical industry, and protect the public through food safety and forensics testing applications.

Qiagen NV Announces Auditor Changes

At a meeting held on May 5, 2015, the Supervisory Board of Qiagen NV approved the dismissal of Ernst & Young GmbH Wirtschaftspr fungsgesellschaft and all EY member firms (EY) as independent registered public accounting firm of the company effective May 5, 2015. The company approved KPMG Accountants N.V. as its independent registered public accounting firm for the fiscal year ending December 31, 2015. The audit committee approved the change in independent registered public accounting firms on May 5, 2015, subject To Approve the shareholders.

Qiagen N.V. Expands Relationship with BGI to Provide Qiagen's Ingenuity Variant Analysis

Qiagen N.V. reported that it has expanded its relationship with BGI to provide Qiagen's Ingenuity Variant Analysis in integrated bioinformatics for all customers of BGI's sequencing services. under the reseller agreement, BGI customers will receive sequencing data generated from their samples through Ingenuity Variant Analysis' secure, cloud-based environment and gain access to its gene variant data and genomic interpretation applications.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
QIA:GR €22.79 EUR +0.291

QIA Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Bio-Reference Laboratories Inc $33.35 USD -0.41
BioMerieux €103.75 EUR +4.08
Cepheid $56.71 USD -1.36
Myriad Genetics Inc $34.60 USD +0.13
PerkinElmer Inc $53.39 USD 0.00
View Industry Companies
 

Industry Analysis

QIA

Industry Average

Valuation QIA Industry Range
Price/Earnings 53.3x
Price/Sales 4.4x
Price/Book 2.4x
Price/Cash Flow 40.0x
TEV/Sales 3.4x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact QIAGEN N.V., please visit www.qiagen.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.